Search In this Thesis
   Search In this Thesis  
العنوان
Plasminogen activator and plasminogen activator - inhibitor - i in lymphoma /
الناشر
Heba Mahmoud El-Eraky,
المؤلف
El-Eraky, Heba Mahmoud.
هيئة الاعداد
باحث / هبة محمود العراقى
مشرف / محمد على محمد عوض
مشرف / إيناس عبد الحليم
مشرف / سولافة عبد الرؤوف الشعراوى
الموضوع
Plasminogen Activator, Tissue-Type-- therapeutic use. Lymphoma-- complications.
تاريخ النشر
1996.
عدد الصفحات
158 p. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
علم الأعصاب السريري
تاريخ الإجازة
01/01/1996
مكان الإجازة
جامعة المنصورة - كلية الطب - Clinical pathology
الفهرس
Only 14 pages are availabe for public view

from 181

from 181

Abstract

Malignant lymphoma - is considered the third most frequent neoplastic disease (El-Bolkainy et aL, 1991) in Egypt. Haemostatic complications are the second most common cause of mortality in lymphoma (Luzzato and Schafer, 1990). These may be presented either by haemorrhagic or thrombotic manifestations. The mechanism of this are multifactorial,, either due to quantitative or qualitative platelet abnormalities, abnormalities of coagulation cascade,, or impaired fibrinolytic system (Ratnoff, 1989). So, we planned this work to clarify the role of fibrinolytic system in the development of thrombotic manifestation in patients with lymphoma. In order to achief this goal, this study were carried out on 74 patients with mah ant lymphoma, 20 cases at the time of diagnosis and 54 cases after complete remission either by chemotherapy, radiotherapy or both as well as 20 apparently healthy individual as control group. Patients were diagnosed by clinical findings peripheral hemogram, bone marrow aspiration and diagnosis is confirmed by histopathological. examination of the affected lymph nodes or spleen. According to histopathological examination of the affected lymph nodes, the patients were grouped into:-